references/iso13485_audit_playbook.md
ISO 13485:2016 Internal Audit Playbook
This reference answers exactly one decision: how do we conduct an ISO 13485 QMS internal audit (Clause 8.2.4) that satisfies certification body expectations and supports MDR / FDA QSR alignment?
Pair with scripts/audit_schedule_optimizer.py (this skill) for cadence and with compliance-os/scripts/audit_simulator.py for mock-audit preparation.
When to Use This Playbook
- Annual Clause 8.2.4 internal audit programme
- Pre-stage-1 ISO 13485 certification readiness
- Surveillance audit preparation (year 2 / year 3)
- New medical device introduction (DHF closure audit)
- Post-CAPA closure verification audit
- Bridge audit for FDA QSR / EU MDR alignment
Key Difference from ISO 27001 Audits
ISO 13485 audits emphasize:
- Design controls (Clause 7.3) — DHF/DMR completeness, design verification + validation evidence, traceability matrix
- Process validation (Clause 7.5.6) — IQ/OQ/PQ for manufacturing + sterilization + cleaning processes
- Document control (Clause 4.2) — strict version control + change control for all controlled documents
- CAPA (Clause 8.5.2) — closed-loop with root cause analysis; "containment / correction / corrective action" distinction
- Post-market surveillance (Clause 8.2.1) — vigilance reporting, customer feedback loop, trend analysis
- Risk management (Clause 7.1 + ISO 14971) — risk file maintained across product lifecycle
ISO 13485 audits are more prescriptive than 27001 — auditors expect specific record formats, sign-offs, and traceability that 27001's risk-based approach does not require.
The 7-Phase Audit Workflow
Same 7-phase structure as ISO 27001 (Plan → Prepare → Open → Field → Close → Report → Track), with these QMS-specific differences:
Phase 1 Plan — Scope Selection
ISO 13485 organizes clauses by lifecycle activity. Audit fieldwork organizes by:
- Design controls (Clause 7.3) — DHF audit per product
- Production & service provision (Clause 7.5) — process validation evidence
- Management responsibility (Clause 5) — management review records
- Resource management (Clause 6) — competence + infrastructure + work environment
- Measurement, analysis, improvement (Clause 8) — internal audit programme + CAPA + nonconformity + statistical techniques
3-year rolling coverage: every clause audited at least once, with design + CAPA + post-market in higher rotation due to risk weight.
Phase 4 Field — QMS-Specific Sampling
For design controls (Clause 7.3) — sample DHFs:
- Stratified by product class (Class I, IIa, IIb, III per MDR; Class I/II/III per FDA)
- For each sampled DHF, verify:
- Design + development plan with stages + reviews defined
- Design inputs traceability to user needs / clinical requirements
- Design outputs verification evidence
- Design validation evidence (clinical evaluation per MDR Annex XIV / 510(k) summary per FDA)
- Design transfer evidence
- Design changes controlled per Clause 7.3.9
- DHF complete and archived
For CAPA (Clause 8.5.2) — sample CAPA records:
- Stratified by source (customer complaint, internal audit, management review, nonconformity)
- For each sampled CAPA, verify:
- Problem statement clear + measurable
- Root cause analysis evidence (5 Why, fishbone, Pareto, FMEA — pick the method)
- Containment + correction + corrective action distinction documented
- Effectiveness verification with evidence (re-test or sample post-implementation)
- Closure approved by appropriate authority
For post-market surveillance (Clause 8.2.1) — sample:
- Customer complaint log + investigation closure
- Vigilance reports (serious incident / FSCA) submitted per applicable regulation
- Trend analysis evidence + management review input
- Post-market clinical follow-up evidence (per MDR for high-risk devices)
Common Stage 1 / Stage 2 Findings (the patterns)
Based on practitioner reports of common ISO 13485:2016 findings:
- Design changes not always controlled per Clause 7.3.9 — emergency changes bypass review
- DHF incomplete — design history files missing one or more required elements
- Process validation incomplete or stale — IQ/OQ/PQ done at original setup, never re-validated
- CAPA effectiveness verification missing — corrective action closed without evidence of effectiveness
- Risk management file not updated post-launch — ISO 14971 risk file frozen at release
- Supplier evaluations exist but selection criteria not documented
- Internal audit programme misses some clauses over 3-year cycle
- Management review missing required inputs (audit results, nonconformity status, customer feedback, etc.)
- Training records lack evidence of effectiveness verification
- Document control: obsolete documents accessible in shared drives
- Validation of software used in QMS (per Clause 4.1.6) not performed
- Post-market surveillance plan exists but not executed quarterly
MDR 2017/745 + FDA QSR Overlap
ISO 13485 is the foundation for both EU MDR and FDA QSR compliance.
EU MDR cross-walk
| ISO 13485 clause | MDR article / annex | |---|---| | 4.2 Documentation | Annex II + Annex III (technical documentation) | | 5 Management responsibility | Article 10(1)-(9) | | 6 Resource management | Article 10(13) | | 7.1 Risk management | Annex I §3 + ISO 14971 | | 7.3 Design + development | Annex II + Annex VIII (design dossier) | | 7.4 Purchasing | Article 10(4) + Annex II | | 7.5.6 Process validation | Annex IX §3 | | 8.2.1 Post-market surveillance | Article 83 + Article 86 + Annex III | | 8.5.2 CAPA | Article 87 (vigilance) + Article 89 (CAPA) |
FDA legacy QSR (21 CFR 820, historical) cross-walk
⚠️ STATUS — QMSR transition (effective 2026-02-02): FDA's QMSR final rule (89 FR 7496) amended 21 CFR Part 820 to incorporate ISO 13485:2016 by reference and removed the legacy QSR subsection structure. The 820.x numbers below no longer exist in the CFR — they are retained only as a familiar index for auditors mapping pre-2026 documentation. Cite the ISO 13485 clauses in current audits.
| ISO 13485 clause (current authority) | Legacy QSR section (historical, pre-2026) | |---|---| | 4 QMS | 820.20 (Management responsibility) + 820.5 (QMS) | | 7.3 Design controls | 820.30 | | 7.4 Purchasing controls | 820.50 | | 7.5.6 Process validation | 820.75 | | 8.2.1 Post-market | 820.198 (Complaint files) + 803 (MDR reporting — unchanged) | | 8.5.2 CAPA | 820.100 |
FDA finalized the QMSR rule in February 2024 (89 FR 7496) incorporating ISO 13485:2016 into 21 CFR 820, substantially harmonizing US and international requirements; it took effect 2026-02-02. An ISO 13485-certified QMS now substantially satisfies 21 CFR 820, with FDA-specific overlays in retained 820.10/820.35/820.45 (labeling, complaint records) and unchanged 21 CFR 803 MDR reporting.
Risk Management Audit (ISO 14971 Crosswalk)
Per Clause 7.1 + ISO 14971:2019, the risk management file (RMF) must be maintained for the device lifecycle. Audit should sample:
- Risk management plan exists per product
- Hazard identification covers reasonable foreseeable misuse
- Risk analysis applies probability × severity per ISO 14971
- Risk control measures applied per inherent safety → protective measures → information for safety hierarchy
- Residual risk evaluated + accepted (with rationale)
- Post-production information feeds back into RMF (concept drift equivalent for medical devices)
CAPA Discipline — The Highest-Stakes Audit Area
CAPA is the #1 cited area in 13485 + QSR audits. Auditors look for:
- Containment vs correction vs corrective action distinction
- Containment: stop the bleeding (short-term)
- Correction: fix the symptom (medium-term)
- Corrective action: prevent recurrence by addressing root cause (long-term)
- Root cause analysis depth — 5 Why minimum; ideally fishbone + Pareto for repeat issues
- Effectiveness verification — measurable evidence the root cause is addressed; not "we updated the procedure"
- Time to close — tracked + reported; aging CAPAs > 90 days are a smell
- Trend analysis — repeat CAPAs across products signal systemic issue
Cross-Framework Reuse
This ISO 13485 audit playbook supports:
- EU MDR 745 — design dossier + technical documentation audits (see mdr-745-specialist)
- FDA QSR (21 CFR 820) — substantially harmonized post Feb 2026
- ISO 14971 — risk management file audit integrated with 7.1
- ISO 42001 for AI-enabled medical devices — A.6 lifecycle controls layer on top of 7.3 design controls
Pair with compliance-os/references/multi_framework_audit_playbook.md for medical-device multi-framework programs.
When This Reference Doesn't Help
- Specific medical device classification. See mdr-745-specialist + fda-consultant-specialist.
- Specific clinical evaluation. Per MDR Annex XIV; see mdr-745-specialist references.
- Software as medical device (SaMD). IEC 62304 specific; see risk-management-specialist + applicable references.
- External notified body audit. This is the internal audit playbook; external surveillance audits follow ISO 17021.
Source authorities (non-exhaustive):
- ISO 13485:2016 — Medical devices — Quality management systems (the standard)
- ISO 14971:2019 — Application of risk management to medical devices
- ISO/IEC 19011:2018 — Guidelines for auditing management systems
- ISO 17021-1:2015 — Conformity assessment requirements
- Regulation (EU) 2017/745 — Medical Device Regulation
- 21 CFR 820 — FDA Quality System Regulation (QSR / QMSR post-Feb 2026)
- FDA Final Rule (Feb 2024) — Quality Management System Regulation (incorporating ISO 13485 by reference)
- AAMI TIR45:2012 — Guidance on use of agile practices in development of medical device software
- IEC 62304:2006/A1:2015 — Medical device software lifecycle
- GHTF / IMDRF guidance documents — international harmonization context